A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
about
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerEpigenetic treatment of solid tumours: a review of clinical trialsIntegrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potentialBelinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective reviewDevelopment of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerTrials with 'epigenetic' drugs: an updateMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerEpigenetic polypharmacology: from combination therapy to multitargeted drugsResistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivoHDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cellsFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentDiscovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-expression network analysis on breast cancer data.Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approachesAn epigenomic approach to therapy for tamoxifen-resistant breast cancerReversal of deficits in dendritic spines, BDNF and Arc expression in the amygdala during alcohol dependence by HDAC inhibitor treatment.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsReduced ING1 levels in breast cancer promotes metastasisHigh nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo.Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the BreastEfficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of AktCurrent and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphomaBiomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpressionHistone deacetylase inhibitors: emerging mechanisms of resistance.Targeted therapies for ER+/HER2- metastatic breast cancer.Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.
P2860
Q26749421-9639E4AF-CB90-4616-9CA3-723AC56F0F6AQ26770482-0269B6ED-34F1-43E6-89F3-B0C4B82F8BBCQ26773803-1B0B73F7-1CEC-4D1C-B217-DFB4B4F7FA2DQ26782613-658ECBBE-6D8D-4698-98A3-973636B5C0C6Q26796449-8FA38849-4D2A-41E3-94ED-01D8C83BC43CQ26825584-E23BF471-442E-4962-8F0A-A374D319EA34Q27000542-9E6AD169-AD88-4FB1-B648-BFCE4A430891Q27001260-4EA34709-E743-45C1-B213-1A15CD56733BQ28067666-7FB9D544-10E9-4ABC-A189-A9063373BF38Q28485252-BDF523F8-783C-4500-A8EE-A7DB3E7D01D8Q28486529-BE42AE73-6D52-4630-81C4-4270F0E5DFDCQ28533949-C55A8A4A-DEA9-49B4-B69F-DD17CE1CC192Q31047698-407D9CCA-3A61-4788-B7C6-DEDC656145EEQ33419858-97862E8E-5EDD-4E9E-B60A-084B993CEA79Q33429255-C51232BC-9C2D-4733-908B-C8FBBC104F07Q33430193-59B55142-DA9A-4252-A760-6A0B9DE69F90Q33432199-DCF74EC4-66CA-4C41-9FF2-9FC7D054E92FQ33643334-777CEE2C-9A7E-401D-8048-B70B4CB2E646Q33689457-4909326C-B226-4752-9B0E-FC00A8A85459Q33835913-51905265-00B4-4911-B485-B60718050557Q33859350-87B9F070-B3A7-4569-AD7C-6EEF1BF21470Q33887916-3D4081D9-AA1E-4529-B9FC-E60935430DA6Q34023704-5E97ACF1-FFDD-440E-BFE4-1744079DF6C5Q34100927-4F6A52E3-B072-4022-A689-0A0DFCF75962Q34107754-200B6400-20AB-42FA-8D29-FAB0A1FE5B38Q34147910-0ADB3190-38BD-42E4-9EA6-49874F441F54Q34326588-6DC81CDC-F80D-469D-85A0-9F53D62EAF17Q34528291-44516A3D-E0B6-4B38-B17D-B155F5A190BFQ34547465-AB38C914-8289-471C-BF2C-46A5E1152C79Q34693969-486C2840-DACB-4C9D-AD14-2F87F307C3D2Q34779627-8AB90EF1-507E-4D14-BFC4-650A351EBF8DQ34852154-9B9CF857-B007-49AE-B701-9230343E7F70Q35000789-E99C774A-D7DF-4EB1-AEBE-ED89E9CDC75FQ35051804-6ED326D7-63FE-4422-A80F-38A3253B6CA6Q35108007-72077390-6932-4D26-B3F4-712BDBB3D4F6Q35201384-76F26EC6-96E5-4679-8552-C9534A3811E6Q35592607-E942FD18-508B-4706-B587-0913E22F0A2EQ35658860-B44A6857-4516-4963-92D3-89A91FC092FDQ35687574-3E37F783-C982-40B7-9DFB-9E10A4759AAEQ35726371-DE42B73A-A217-494E-BBEC-A06314317CDE
P2860
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase II study of the histon ...... herapy-resistant breast cancer
@ast
A phase II study of the histon ...... herapy-resistant breast cancer
@en
type
label
A phase II study of the histon ...... herapy-resistant breast cancer
@ast
A phase II study of the histon ...... herapy-resistant breast cancer
@en
prefLabel
A phase II study of the histon ...... herapy-resistant breast cancer
@ast
A phase II study of the histon ...... herapy-resistant breast cancer
@en
P2093
P2860
P356
P1476
A phase II study of the histon ...... herapy-resistant breast cancer
@en
P2093
P N Munster
R Ismail-Khan
S E Minton
P2860
P2888
P304
P356
10.1038/BJC.2011.156
P407
P577
2011-05-10T00:00:00Z